June 21, 2022
1 min watch
Save
VIDEO: Impact of stem cell transplants in myeloma treatment ‘remarkable’
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
In this video, Paul Richardson, MD, director of clinical research at Jerome Lipper Multiple Myeloma Center at Dana-Farber Cancer Institute, discusses the phase III DETERMINATION study in multiple myeloma presented at ASCO Annual Meeting.
Richardson discusses one of the major findings of the study, which was a significant difference between the length of progression-free survival between the early transplant arm of the cohort and the no-transplant arm.
“This was really encouraging and we thought quite remarkable, and to some extent unexpected,” Richardson said. “We expected at least a year, but we saw substantially more than that.”
Reference:
- Richardson P, et al. Presented at: 2022 ASCO Annual Meeting; June 3-7, 2022; Chicago.
Published by:
Sources/Disclosures
Collapse
Source:
Healio Interview
Disclosures:
Richardson reports consulting for and/or receiving research support from AstraZeneca, Celgene/BMS, GSK, Karyopharm, Oncopeptides, Protocol Intelligence, Regeneron, Sanofi, Secura Bio and Takeda.
Read more about
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.